TABLE 2.

Comparison of the new recombinant IgG line blot assay with the previous recombinant IgG Western blot and line blot assays using the same antigens as in the recombinant IgG blot assay

GroupaNo. of seraNo. (%) of positive sera in assay
Western blotLine blotbLine blot with additional antigens
EM155 (33.3)7 (46.7)8 (53.3)
NB5036 (72.0)43 (86.0)44 (88.0)
ACA109 (90.0)10 (100.0)10 (100.0)
AT1010 (100.0)9 (90.0)10 (100.0)
All LB cases8560 (70.6)69 (81.2)72 (84.7)
Controls1101 (0.9)0 (0.0)1 (0.9)
  • a EM, erythema migrans; NB, neuroborreliosis (stage II); ACA, acrodermatitis chronica atrophicans (stage III); AT, Lyme arthritis (stage III); all LB cases, Lyme borreliosis. Controls were blood donors (n = 60), patients with syphilis (n = 10), patients with positive rheumatoid factor (n = 10), and patients with fever of unknown origin (n = 30).

  • b Using only antigens already evaluated in the previous recombinant IgG Western blot assay.